<< Back to News

New FDA Approval for Merck's KEYTRUDA®

June 12, 2018 – Merck  announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®  the company’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (C